drugset
drugset / Trial / NCT06006169

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06006169 ↗

Phase 2 Recruiting 186 enrolled Sichuan Baili Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors.

Timeline

Start
2023-10-20
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Izalontamab Brengitecan Unknown — Intravenous
Subject SI-B003 Monoclonal antibody — Intravenous

Indications

head and neck squamous cell carcinoma